Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nigel Leigh

Showing results (111-120 of 149) with videos related to

Pageof 15
Sort By:
Human Brain Mapping|June 3, 2023
Network connectivity and structural correlates of survival in progressive supranuclear palsy and corticobasal syndromeDavid J Whiteside, Duncan Street, Alexander G Murley, et al.
European Journal of Human Genetics : EJHG|April 25, 2013
Homozygosity analysis in amyotrophic lateral sclerosisKin Mok, Hannu Laaksovirta, Pentti J Tienari, et al.
Science (New York, N.Y.)|March 1, 2008
TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosisJemeen Sreedharan, Ian P Blair, Vineeta B Tripathi, et al.
Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases|March 16, 2010
The sex ratio in amyotrophic lateral sclerosis: A population based studyZita R Manjaly, Kirsten M Scott, Kumar Abhinav, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|September 2, 2016
Rare genetic variation in UNC13A may modify survival in amyotrophic lateral sclerosisBenjamin Gaastra, Aleksey Shatunov, Sara Pulit, et al.
Ebiomedicine|July 12, 2020
Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trialWilliam Camu, Marius Mickunas, Jean-Luc Veyrune, et al.
The Lancet. Neurology|February 1, 2017
Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trialVincent Meininger, Angela Genge, Leonard H van den Berg, et al.
Annals of the New York Academy of Sciences|May 21, 2024
Pharmacometabolomics applied to low-dose interleukin-2 treatment in amyotrophic lateral sclerosisHugo Alarcan, Clément Bruno, Patrick Emond, et al.
Neurobiology of Aging|April 17, 2013
Residual association at C9orf72 suggests an alternative amyotrophic lateral sclerosis-causing hexanucleotide repeatAshley R Jones, Ione Woollacott, Aleksey Shatunov, et al.
Brain Communications|August 19, 2021
Amyotrophic lateral sclerosis transcriptomics reveals immunological effects of low-dose interleukin-2Ilaria Giovannelli, Nadhim Bayatti, Abigail Brown, et al.
Pageof 15

Showing results (111-120 of 149) with videos related to

Sort By:
Pageof 15
Human Brain Mapping|June 3, 2023
Network connectivity and structural correlates of survival in progressive supranuclear palsy and corticobasal syndromeDavid J Whiteside, Duncan Street, Alexander G Murley, et al.
European Journal of Human Genetics : EJHG|April 25, 2013
Homozygosity analysis in amyotrophic lateral sclerosisKin Mok, Hannu Laaksovirta, Pentti J Tienari, et al.
Science (New York, N.Y.)|March 1, 2008
TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosisJemeen Sreedharan, Ian P Blair, Vineeta B Tripathi, et al.
Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases|March 16, 2010
The sex ratio in amyotrophic lateral sclerosis: A population based studyZita R Manjaly, Kirsten M Scott, Kumar Abhinav, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|September 2, 2016
Rare genetic variation in UNC13A may modify survival in amyotrophic lateral sclerosisBenjamin Gaastra, Aleksey Shatunov, Sara Pulit, et al.
Ebiomedicine|July 12, 2020
Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trialWilliam Camu, Marius Mickunas, Jean-Luc Veyrune, et al.
The Lancet. Neurology|February 1, 2017
Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trialVincent Meininger, Angela Genge, Leonard H van den Berg, et al.
Annals of the New York Academy of Sciences|May 21, 2024
Pharmacometabolomics applied to low-dose interleukin-2 treatment in amyotrophic lateral sclerosisHugo Alarcan, Clément Bruno, Patrick Emond, et al.
Neurobiology of Aging|April 17, 2013
Residual association at C9orf72 suggests an alternative amyotrophic lateral sclerosis-causing hexanucleotide repeatAshley R Jones, Ione Woollacott, Aleksey Shatunov, et al.
Brain Communications|August 19, 2021
Amyotrophic lateral sclerosis transcriptomics reveals immunological effects of low-dose interleukin-2Ilaria Giovannelli, Nadhim Bayatti, Abigail Brown, et al.
Pageof 15